The translocated EGFR suppresses miR‐26a/b expression in the liver stromal cells and activates the secretion of hepatocyte growth factor (HGF), which ultimately binds to the c‐MET receptor on the DTCs, promoting cancer proliferation in vitro and in vivo (Zhang et al., 2017) (Figure 1c). The gene discussed is HGF; the disease is cancer.